Adicet Bio, Inc. (ACET) Insider Trading Activity
NASDAQ$0.6449
Market Cap
$53.34M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
402 of 877
Rank in Industry
234 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ACET Insider Trading Activity
ACET Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $8,437 | 1 | 100 |
Related Transactions
| Kauffman Michael | director | 0 | $0 | 1 | $8,437 | $-8,437 |
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Insider Activity of Adicet Bio, Inc.
Over the last 12 months, insiders at Adicet Bio, Inc. have bought $0 and sold $8,437 worth of Adicet Bio, Inc. stock.
On average, over the past 5 years, insiders at Adicet Bio, Inc. have bought $16.34M and sold $1.76M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,125,000 shares for transaction amount of $7.5M was made by ORBIMED ADVISORS LLC () on 2024‑01‑25.
List of Insider Buy and Sell Transactions, Adicet Bio, Inc.
| 2024-06-05 | Sale | Kauffman Michael | director | 5,900 0.0071% | $1.43 | $8,437 | -26.39% | |
| 2024-01-25 | ORBIMED ADVISORS LLC | 3.13M 7.0488% | $2.40 | $7.5M | -41.70% | |||
| 2024-01-25 | GORDON CARL L | 3.13M 7.0488% | $2.40 | $7.5M | -41.70% | |||
| 2023-10-02 | Schor Chen | President & CEO | 5,500 0.013% | $1.33 | $7,340 | +13.74% | ||
| 2023-09-29 | Sale | Schor Chen | President & CEO | 5,500 0.0127% | $1.36 | $7,481 | +9.12% | |
| 2023-09-28 | Sale | Schor Chen | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +4.93% | |
| 2023-09-28 | Schor Chen | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +4.93% | ||
| 2023-06-30 | DUBIN STEVE | director | 5,000 0.0115% | $2.40 | $12,000 | -27.78% | ||
| 2023-06-27 | ORBIMED ADVISORS LLC | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | |||
| 2023-06-27 | GORDON CARL L | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | |||
| 2023-02-15 | Sale | Healey Don | Chief Technology Officer | 4,533 0.0101% | $7.57 | $34,327 | -68.06% | |
| 2023-02-10 | Sale | Healey Don | Chief Technology Officer | 10,467 0.0247% | $7.98 | $83,476 | -68.37% | |
| 2022-11-10 | Sale | Schor Chen | President & CEO | 39,955 0.095% | $20.30 | $811,242 | -72.57% | |
| 2022-11-10 | Sale | Aftab Blake | Chief Scientific Officer | 6,967 0.0171% | $21.00 | $146,307 | -72.57% | |
| 2022-11-07 | Sale | Schor Chen | President & CEO | 30,000 0.0726% | $19.05 | $571,488 | -69.94% | |
| 2022-11-03 | Sale | Schor Chen | President & CEO | 24,813 0.06% | $18.04 | $447,718 | -68.15% | |
| 2022-11-02 | Sale | Schor Chen | President & CEO | 500 0.0013% | $18.00 | $9,000 | -66.45% | |
| 2022-10-19 | Sale | Aftab Blake | Chief Scientific Officer | 8,067 0.0198% | $16.27 | $131,250 | -62.28% | |
| 2022-10-12 | Sale | Aftab Blake | Chief Scientific Officer | 1,646 0.0039% | $15.40 | $25,348 | -61.43% | |
| 2022-09-14 | Sale | Schor Chen | President & CEO | 952 0.0023% | $18.00 | $17,136 | -57.93% |
Total: 58
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Kauffman Michael | director | 5900 0.0071% | $3,804.91 | 0 | 1 | |
| ORBIMED ADVISORS LLC | 7526359 9.0997% | $4.85M | 3 | 0 | <0.0001% | |
| GORDON CARL L | 7526359 9.0997% | $4.85M | 2 | 0 | <0.0001% | |
| SILVERSTEIN JONATHAN | 4830387 5.8402% | $3.12M | 1 | 0 | ||
| PureTech Health LLC | 10 percent owner | 2119696 2.5628% | $1.37M | 1 | 6 | |
| Sinclair Andrew | director | 2115385 2.5576% | $1.36M | 1 | 0 | <0.0001% |
| Jakobovits Aya | 356343 0.4308% | $229,805.60 | 0 | 10 | ||
| Healey Don | Chief Technology Officer | 66568 0.0805% | $42,929.70 | 0 | 2 | |
| Galimi Francesco | SVP & Chief Medical Officer | 59917 0.0724% | $38,640.47 | 0 | 1 | |
| Schor Chen | President & CEO | 43469 0.0526% | $28,033.16 | 5 | 18 | +9.34% |
| Aftab Blake | Chief Scientific Officer | 28209 0.0341% | $18,191.98 | 0 | 6 | |
| DUBIN STEVE | director | 10900 0.0132% | $7,029.41 | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$4,613,182 | 103 | -36.00% | $53.34M | |
$15,956,086 | 53 | 5.33% | $49.09M | |
$81,638,324 | 48 | 7.58% | $49.51M | |
$77,062,892 | 41 | 13.96% | $55.77M | |
$6,787,959 | 35 | 49.84% | $56.14M | |
$1,087,418 | 21 | 1.95% | $55.2M | |
$160,539,875 | 21 | -6.57% | $55.97M | |
$167,476,357 | 20 | -1.54% | $50.98M | |
$32,972,199 | 16 | -10.77% | $54.86M | |
$3,682,258 | 10 | -34.11% | $52.22M | |
$3,871,238 | 10 | -30.38% | $53.59M | |
Adicet Bio, Inc. (ACET) | $32,684,649 | 8 | -15.84% | $53.34M |
$91,549,696 | 8 | -6.55% | $49.95M | |
$478,647 | 7 | 69.41% | $50.03M | |
$8,470,804 | 6 | -13.28% | $48.38M | |
$195,184 | 5 | 6.34% | $54.73M | |
$6,049,986 | 4 | -8.38% | $55.66M | |
$1,801,761 | 4 | 54.67% | $48.75M | |
$26,374 | 2 | -53.61% | $51.67M |
ACET Institutional Investors: Active Positions
| Increased Positions | 21 | +25.93% | 1M | +2.18% |
| Decreased Positions | 31 | -38.27% | 3M | -4.45% |
| New Positions | 5 | New | 289,982 | New |
| Sold Out Positions | 12 | Sold Out | 1M | Sold Out |
| Total Postitions | 71 | -12.35% | 57M | -2.27% |
ACET Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Orbimed Advisors Llc | $7,670.00 | 13.79% | 11.45M | 0 | 0% | 2024-12-31 |
| Tang Capital Management Llc | $5,458.00 | 9.81% | 8.15M | -70,972 | -0.86% | 2024-12-31 |
| Ra Capital Management, L.P. | $5,052.00 | 9.09% | 7.54M | 0 | 0% | 2024-12-31 |
| Goldman Sachs Group Inc | $2,514.00 | 4.52% | 3.75M | -7,132 | -0.19% | 2024-12-31 |
| Vanguard Group Inc | $2,148.00 | 3.86% | 3.21M | 0 | 0% | 2024-12-31 |
| Carlyle Group Inc. | $1,976.00 | 3.55% | 2.95M | 0 | 0% | 2024-12-31 |
| Aquilo Capital Management, Llc | $1,696.00 | 3.05% | 2.53M | 0 | 0% | 2024-12-31 |
| Acadian Asset Management Llc | $1,342.00 | 2.41% | 2M | +123,114 | +6.55% | 2024-12-31 |
| Millennium Management Llc | $1,216.00 | 2.19% | 1.81M | -144,413 | -7.37% | 2024-12-31 |
| Blackstone Inc. | $828.00 | 1.49% | 1.24M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.